Ibuprofen 400MG/ 600MG/ 800MG Presolicitation
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DLA TROOP SUPPORT
Contract Value
Not provided
Codes & Classification
Solicitation Number
SPE2D2-21-R-0106
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
The Defense Logistics Agency (DLA) Troop Support has announced a forthcoming solicitation for a national requirements contract to supply Ibuprofen Tablets in various strengths and packaging configurations. This presolicitation notice, identified under procurement number SPE2D2-21-R-0106, outlines the agency’s intent to establish a firm-fixed price, requirements-type contract with a one-year base period and four additional one-year option periods. The contract is designed to ensure a reliable, national supply source for Ibuprofen 400MG (in 30, 90, and 500 count bottles), as well as Ibuprofen 600MG and 800MG (in 90 and 500 count bottles).
The scope of this procurement encompasses the provision of these pharmaceutical products to a broad range of federal customers, including the Department of Defense, Department of Veterans Affairs, Indian Health Service, and the Bureau of Prisons. Distribution will occur through the DLA and VA prime vendor programs, supporting the ongoing healthcare needs of these agencies. The contract will be solicited as a commercial item acquisition under FAR Part 12, and all qualified sources are invited to submit proposals, as this is an unrestricted and fully competitive opportunity.
Key requirements include the ability to manufacture and supply Ibuprofen tablets in the specified dosages and packaging formats, with annual usage estimates to be detailed in the forthcoming Schedule of Supplies. The selected contractor will be expected to meet all applicable pharmaceutical manufacturing standards as defined under NAICS Code 325412 (Pharmaceutical Preparation Manufacturing) and Product Service Code 6505.
Interested parties should note that the solicitation will be posted on the DLA Bid Board System (DIBBS) and on SAM.gov. Prospective offerors are encouraged to monitor these platforms for updates and to set up automated notifications for any changes to the solicitation. The anticipated release date for the solicitation is projected for April 2021, though DLA reserves the right to adjust this timeline as necessary.
There are no set-aside requirements or special restrictions indicated; the acquisition is open to all capable sources. For further information or to address any questions, interested vendors should contact Kevin Rafferty at [email protected] or by phone at 215-737-0907.
This opportunity represents a significant, multi-year contract to support the pharmaceutical needs of key federal agencies, and contractors with the requisite manufacturing capabilities and distribution experience are encouraged to review the solicitation upon its release.